A Randomized, Multi Center, Double Blind, Comparative Phase III Study to Evaluate the Safety and Immunogenicity of BBILs monovalent Type 3 Oral Polio Vaccine Vs Pre-Qualified trivalent Oral Polio Vaccine In healthy neonates. (non- inferiority trial) - Monovalent OPV type III

Start Date13 Nov 2009

Sponsor / Collaborator

Bharat Biotech International Ltd.

CTRI/2010/091/000203 / CompletedPhase 3

A Randomized, Multi Center, Double Blind, Comparative Phase III Study to Evaluate the Safety and Immunogenicity of BBILs monovalent Type 1 Oral Polio Vaccine Vs Pre-Qualified trivalent Oral Polio Vaccine In Healthy Neonates. (non- inferiority trial)

Start Date28 Aug 2009

Sponsor / Collaborator

Bharat Biotech International Ltd.

ISRCTN80143849 / CompletedNot Applicable

Comparative evaluation of immunogenicity of Monovalent Type 1 Oral Poliovirus Vaccine (mOPV1) versus trivalent OPV (tOPV): a randomised double-blind trial set in India (Panacea Biotec Ltd mOPV1 study)

Start Date25 Oct 2005

Sponsor / Collaborator

Panacea Biotec Ltd.

100 Clinical Results associated with monovalent oral polio vaccine type 1 (mOPV1) (Panacea Biotec)

100 Translational Medicine associated with monovalent oral polio vaccine type 1 (mOPV1) (Panacea Biotec)

100 Patents (Medical) associated with monovalent oral polio vaccine type 1 (mOPV1) (Panacea Biotec)

Literatures (Medical) associated with monovalent oral polio vaccine type 1 (mOPV1) (Panacea Biotec)

01 Oct 2022·Emerging Infectious Diseases

Importation and Circulation of Vaccine-Derived Poliovirus Serotype 2, Senegal, 2020–2021

Article

Author: Faye, Martin ; Diop, Boly ; Diop, Ousmane Madiagne ; Dia, Ndongo ; Kiori, Davy Evrard ; Kébé, Ousmane ; Dia, Hamet ; Faye, Ousmane ; Diallo, Jean Pierre ; Ndiaye, NDack ; Sall, Amadou Alpha ; Diallo, Aliou ; Dosseh, Annick ; Sam, Abdoulaye

Environmental surveillance for poliovirus is increasingly used in poliovirus eradication efforts as a supplement to acute flaccid paralysis (AFP) surveillance. Environmental surveillance was officially established in 2017 in Senegal, where no poliovirus had been detected since 2010. We tested sewage samples from 2 sites in Dakar monthly for polioviruses. We identified a vaccine-derived poliovirus serotype 2 on January 19, 2021, from a sample collected on December 24, 2020; by December 31, 2021, we had detected 70 vaccine-derived poliovirus serotype 2 isolates circulating in 7 of 14 regions in Senegal. Sources included 18 AFP cases, 20 direct contacts, 17 contacts in the community, and 15 sewage samples. Phylogenetic analysis revealed the circulation of 2 clusters and provided evidence on the virus introduction from Guinea. Because novel oral polio vaccine serotype 2 was used for response activities throughout Senegal, we recommend expanding environmental surveillance into other regions.

02 May 2022·International HealthQ4 · MEDICINE

Tracking immunization coverage, dropout and equity gaps among children ages 12–23 months in Malawi – bottleneck analysis of the Malawi Demographic and Health Survey

Q4 · MEDICINE

Article

Author: Ntenda, Peter A M ; Mmanga, Kondwani ; Mwenyenkulu, Tisungane E ; Nkoka, Owen

AbstractBackgroundBetween 2010 and 2016, the proportion of children 12–23 months of age who received full immunization in Malawi decreased from 81% to 76%. Most studies on immunization have mainly focused on the risk factors of vaccination coverage while data on dropouts and equity gaps is very scanty. Thus the aim of the present study was to describe the trend in immunization coverage, dropout rates and effective immunization coverage (EIC) among children ages 12–23 months in Malawi.MethodsSecondary analyses of the cross-sectional data obtained from the three waves of the Demographic and Health Surveys (2004, 2010 and 2015–16) were conducted. Using bottleneck analysis, outputs were generated based on service coverage, demand/equity (service utilization) and quality (full immunization). The World Health Organization benchmarks were used to assess gaps in the immunization coverage indicators.ResultsThe coverage was >90.0% in most of the antigens while full immunization status was estimated at 65%, 84% and 73% in 2004, 2010 and 2015, respectively. The highest coverage was observed in Bacillus Calmette–Guérin (BCG) and lowest in oral polio vaccine 1 (OPV1). OPV1 coverage was <90% in the 2004 cohort year, while pentavalent 3 (Penta3) and measles-containing vaccine 1 (MCV1) coverages were <90% in 2004. Dropout rates of Penta3 and MCV1 were significantly >10% in 2004. The logistic regression analyses showed that children were significantly less likely to be immunized with Penta3 and MCV1 in all cohort years compared with Penta1.ConclusionsAlthough immunization coverage was in line with the national and district targets for various antigens, full vaccination coverage (FVC) is still lagging behind. Furthermore, the dropout rates for Penta3 and MCV1 showed upside U-shaped patterns. Thus health education, supervision and orientation of service providers are urgently needed to address disparities that are existing in FVC.

01 Dec 2019·International Journal for Equity in HealthQ2 · MEDICINE

Wealth-based equity in maternal, neonatal, and child health services utilization: a cross-sectional study from Ethiopia

Q2 · MEDICINE

ArticleOA

Author: Okwaraji, Yemisrach Behailu ; Persson, Lars Åke ; Wuneh, Alem Desta ; Schellenberg, Joanna ; Bezabih, Afework Mulugeta ; Medhanyie, Araya Abrha

AbstractBackgroundDespite the pro-poor health policies in Ethiopia, the utilization of maternal, neonatal, and child health services remains a challenge for the country. Health equity became central in the post-2015 Sustainable Development Goals globally and is a priority for Ethiopia. The aim of this study was to assess equity in utilization of a range of maternal and child health services by applying absolute and relative equity indices.MethodsData on maternal and child health utilization emanated from a baseline survey conducted for a large project ‘Optimizing the Health Extension Program from December 2016 to February 2017 in four regions of Ethiopia. The utilization of four or more antenatal care visits; skilled birth attendance; postnatal care within 2 days after childbirth; immunization with BCG, polio 3, pentavalent 3, measles and full immunization of children aged 12–23 months; and vitamin A supplementation for 6–23 months old children were stratified by wealth quintiles. The socioeconomic status of the household was assessed by household assets and measured by constructing a wealth index using principal component analysis. Equity was assessed by applying two absolute inequity indices (Wealth index [quintile 5- quintile 1] and slope index of inequality) and two relative inequity indices (Wealth index [quintile5: quintile1] and concentration index).ResultsThe maternal health services utilization was low and inequitably distributed favoring the better-off women. About 44, 71, and 18% of women from the better-off households had four or more antenatal visits, utilized skilled birth attendance and postnatal care within two days compared to 20, 29, and 8% of women from the poorest households, respectively. Skilled birth attendance was the most inequitably distributed maternal health service. All basic immunizations: BCG, polio 3, pentavalent 3, measles, and full immunization in children aged 12–23 months and vitamin A supplementation were equitably distributed.ConclusionUtilization of maternal health services was low, inequitable, and skewed against women from the poorest households. In contrast, preventive child health services were equitably distributed. Efforts to increase utilization and reinforcement of pro-poor and pro-rural strategies for maternal, newborn and immunization services in Ethiopia should be strengthened.

100 Deals associated with monovalent oral polio vaccine type 1 (mOPV1) (Panacea Biotec)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
poliomyelitis due to poliovirus type I	IN	Panacea Biotec Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

monovalent oral polio vaccine type 1 (mOPV1) (Panacea Biotec)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation